Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study

H Yu, L Lin, Z Zhang, H Zhang, H Hu - Signal transduction and targeted …, 2020 - nature.com
NF-κB pathway consists of canonical and non-canonical pathways. The canonical NF-κB is
activated by various stimuli, transducing a quick but transient transcriptional activity, to …

CRISPR activation and interference screens decode stimulation responses in primary human T cells

R Schmidt, Z Steinhart, M Layeghi, JW Freimer… - Science, 2022 - science.org
Regulation of cytokine production in stimulated T cells can be disrupted in autoimmunity,
immunodeficiencies, and cancer. Systematic discovery of stimulation-dependent cytokine …

HLA-independent T cell receptors for targeting tumors with low antigen density

J Mansilla-Soto, J Eyquem, S Haubner, M Hamieh… - Nature medicine, 2022 - nature.com
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune
responses. Tumor escape associated with low target antigen expression is emerging as one …

[HTML][HTML] Liquid-liquid phase separation: Orchestrating cell signaling through time and space

Q Su, S Mehta, J Zhang - Molecular cell, 2021 - cell.com
Cell signaling is a complex process. The faithful transduction of information into specific
cellular actions depends on the synergistic effects of many regulatory molecules, nurtured by …

Structural basis of assembly of the human T cell receptor–CD3 complex

D Dong, L Zheng, J Lin, B Zhang, Y Zhu, N Li, S Xie… - Nature, 2019 - nature.com
The αβ T cell receptor (TCR), in association with the CD3γε–CD3δε–CD3ζζ signalling
hexamer, is the primary determinant of T cell development and activation, and of immune …

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

O Dufva, J Koski, P Maliniemi, A Ianevski… - Blood, The Journal …, 2020 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and
refractory B-cell malignancies, but resistance and relapses still occur. Better understanding …

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

M Sharma, H Khong, F Fa'ak, SE Bentebibel… - Nature …, 2020 - nature.com
Abstract High dose interleukin-2 (IL-2) is active against metastatic melanoma and renal cell
carcinoma, but treatment-associated toxicity and expansion of suppressive regulatory T cells …

The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy

S Kandel, P Adhikary, G Li, K Cheng - Cancer letters, 2021 - Elsevier
Immune checkpoint blockade has shown unprecedented and durable clinical response in a
wide range of cancers. T cell immunoglobulin and mucin domain 3 (TIM3) is an inhibitory …

The immunopathogenesis of fibrosis in systemic sclerosis

M Brown, S O'Reilly - Clinical & Experimental Immunology, 2019 - academic.oup.com
Systemic sclerosis (SSc) is an idiopathic systemic autoimmune disease. It is characterized
by a triad of hallmarks: immune dysfunction, fibrosis and vasculopathy. Immune dysfunction …